Stockwatch. Pass the parcel
This article was originally published in Scrip
Adolor’s re-acquisition this week of its rights to Entereg (alvimopan) from partner GlaxoSmithKline (scripintelligence.com, 15 Jun 2011) may provide investors with some useful clues, not just to the commercial potential for returned drugs, but also to the value of health economic analyses in pharmaceutical marketing and the value of the payments for re-acquired rights.
You may also be interested in...
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.
The prices of biotechnology and pharmaceutical sector indices continue to be comparatively robust in the face of big falls in global markets as investors expect new drugs and vaccines to be generated by the sector. While it is largely accepted that the life science sector will eventually ride to the rescue, bumper profits are far from guaranteed.
Pharmaceutical shares are stronger than most as world stock markets dive downwards, but they are not immune to the coronavirus fallout. The effects will be felt by biopharma companies across many areas of their activity.